Resistance invariably develops to anti-androgen therapies used to treat newly diagnosed prostate cancers, but effective treatments for castration-resistant disease remain elusive. Here we report that the transcriptional co-activator CBP/p300 is required to maintain the growth of castration-resistant prostate cancer. To exploit this vulnerability, we developed a novel smallmolecule inhibitor of the CBP/p300 bromodomain that blocks prostate cancer growth in vitro and in vivo. Molecular dissection of the consequences of drug treatment revealed a critical role for CBP/p300 in histone acetylation required for the transcriptional activity of the androgen receptor and its target gene expression. Our findings offer a preclinical proof of concept for small molecule therapies to target the CBP/p300 bromodomain as a strategy to treat castration-resistant prostate cancer.
7 049 and 296.0 → 214.0 for diclofenac. The lower and upper limits of quantitation of the assay for GNE-049 were 0.005 and 10 µM, respectively.
Cell Culture and Proliferation Assays
All prostate cancer cell lines were obtained from ATCC, authenticated by STR and tested to ensure free from mycoplasma with in 3 months of use. All lines were cultured in RPMI1640 media supplemented with 10% fetal bovine serum and 2 mM glutamine, and used for experimentation with in 1 month of thawing from frozen stock. Androgen deprivation was achieved by culturing cells in RPMI media supplemented with 10 % charcoal stripped serum (CCS) (Sigma Aldrich) for at least 5 days. Androgen stimulation was then achieved by addition of 0.1 nM Methyltrienolone (R1881) (Sigma-Aldrich) for at least 24h. Cell proliferation in 2D was evaluated in a 384-well format using CellTiter-Glo® reagent (Promega) according to manufacturer's instructions. 3D growth was assessed by culture in soft agar in a 96 well format. Growth was assessed by colony number and area counts using an optical plate reader.
For assessment of drug combination effects the Bliss independence model was used (25) . The Bliss expectation was determined with the equation (A+B)-A*B, in which A and B are the fractional growth inhibitions induced by agent A and B at a given dose. The difference between the Bliss expectation and the observed growth inhibition with agents A and B used at the same dose is determined to be the Bliss excess. A Bliss sum score was calculated by summing the bliss excess values of all dose combinations. To determine if positive Bliss sum scores represented robust synergy, we ranked our data compared to previous data sets generated in the same manner (26, 27) .
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Membranes were incubated overnight with the following antibodies: AR (Santa Cruz Biotechnology) CBP (Santa Cruz Biotechnology), P300 (Bethyl Labs), Tubulin (DM1a Abcam).
Signal was detected using fluorescently labeled secondary antibodies (IRDye® Li-COR) and the Odyssey CL-x imager (Li-COR). FLAG tagged AR was immune-precipitated from LNCaP nuclear extract, obtained by sequential extraction with hypotonic buffer (10mM HEPES pH 7.9, 10mM
KCl, 1.5mM MgCl2, 0.34M sucrose, 10% glycerol, Triton X 0.1%, 1mM DTT and protease inhibitor) and nuclear lysis buffer (20nM Tris pH8, 10% glycerol, 1% NP40, 2mM EDTA, 400mM
NaCl, 1mM DTT and protease inhibitor). Extracts were incubated with anti-FLAG antibody (Sigma-Aldrich) overnight, before precipitation with protein G magnetic beads (Dynabeads, Thermo). Immune precipitates were washed three times with PBS + 1% NP40, once with PBS, and boiled in SDS sample buffer.
Gene expression analysis
RNA was purified from cells using the RNeasy kit (Qiagen) according to manufacturer's instructions. Quantitative RT-PCR was performed using Taqman assay (ThermoFisher Scientific, Inc.) on ABI QuantStudio 7 Flex real-time PCR system. For whole transcriptome RNAsequencing RNA libraries were made using TruSeq RNA Sample Preparation Kit v2 (Illumina). Size of the libraries was confirmed using Fragment Analyzer (Advanced Analytical Technologies) and their concentration was determined by a qPCR based method using Library Quantification Kit (KAPA). The libraries were multiplexed and then sequenced on Illumina HiSeq2500 (Illumina) to generate 30M of single-end 50 base-pair reads. Data has been made publically available at the European Nucleotide Archive (ENA), project ID PRJEB20821. Gene-Research.
Author Manuscript Published OnlineFirst on August 17, 2017 ; DOI: 10.1158/0008-5472. set enrichment analysis (GSEA) was performed using Broad Institute software (http://software.broadinstitute.org/gsea/index.jsp) 27 . For total mRNA quantification poly adenylated mRNA was isolated from total RNA using the Oligotex mini kit (Qiagen) according to manufacturers instructions, and quantitated using a NanoDrop spectrophotometer (Thermo Scientific).
Chromatin immuno-precipitation and sequencing
After appropriate drug treatment, cells were cross-linked by 15 minute incubation in 1% formaldehyde, then quenched for 5 minutes in 125 mM glycine. Subsequent steps were performed at Active Motif. Cells were lysed and chromatin sheared by sonication to an average length of 300-500 bp. Genomic DNA (Input) was prepared by treating aliquots of chromatin with RNase, proteinase K and heat for de-crosslinking, followed by ethanol precipitation. Pellets were resuspended and the resulting DNA was quantified on a NanoDrop spectrophotometer.
Extrapolation to the original chromatin volume allowed quantitation of the total chromatin yield. 30 μg of chromatin was precleared with protein A agarose beads (Invitrogen). Immunoprecipitation was then carried out using the following antibodies: anti-H3K27Ac (Active motif), anti-AR (Santa Cruz Biotechnology), anti-P300 (Santa Cruz Biotechnology). Reactions were spiked with Drosophila chromatin (Active Motif 53083) and a Drosophila specific antibody (Active Motif 61686) as a mechanism for normalization. Complexes were washed, eluted from the beads with SDS buffer, and subjected to RNase and proteinase K treatment. Crosslinks were reversed by incubation overnight at 65 °C, and ChIP DNA was purified by phenol-chloroform extraction and ethanol precipitation. Reads were aligned to the human genome (GRCh37) using the GSNAP algorithm (version 2013-10-10) with the following settings: "-M 2 -n 10 -B 2 -i 1 --pairmax-dna=1000 --terminal-threshold=1000 --gmap-mode=none --clip-overlap". Fragment length was determined by the strand cross-correlation method. Reads were extended to this fragment length before coverage was calculated at a per-nucleotide level using uniquely mapping reads.
These coverage values were normalized using the coverage from uniquely mapping reads for the Drosophila melanogaster genome as follows. All reads were also aligned to the Drosophila melanogaster genome (version BDGP5.25.64 from Ensembl) using the above GSNAP settings and version. The GRCh37 uniquely mapped coverage values (H) were normalized by the Drosophila uniquely mapped coverage values (D) to produce scaled coverage values (Hs) with the following formula: Hs = (H/D) * 1e6. MACS (PMID: 22936215 version 2.0.10) was used to identify coverage peaks using the default settings. Data has been made publically available at the ENA, project ID PRJEB20981.
Enhancers regions were identified by processing the H3K27Ac ChIP sequence reads and associated MACS 2.0 peaks with the ROSE program (PMID:23582322) using the settings "-g HG19 -t 0". For the comparison of enhancer and Transcription Start Sites (TSS), these enhancers were scaled to a common width of 5kb. TSS regions were centered on the TSS of Research.
Author Manuscript Published OnlineFirst on August 17, 2017; DOI: 10.1158/0008-5472.CAN-17-0314 each NCBI RefSeq transcript (release 53) and set to a common width of 5kb. Coverage, normalized to sample library size, was counted in these regions, for each sample, using 25 bins.
In vivo studies
All procedures were approved by and conformed to the guidelines and principles set by the Institutional Animal Care and Use Committee of Genentech and were carried out in an Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)accredited facility. Prostate cancer Patient-Derived Xenograft tumors (PDXs) were established by passage of tumor fragments (~1 mm 3 ) subcutaneously (s.c.) into 6 to 8 week old recipient mice.
One to three days prior to inoculation with TM00298, female NSG mice (Jackson Laboratories, Sacramento, CA) were inoculated s.c. with 12.5 mg 90-day slow release dihydrotestosterone (DHT) pellets (Innovative Research of America, Sarasota, FLA). TM00298 primary tumor fragments (between passages 2-9) were implanted s.c. in the hind flank into DHT-pellet inoculated NSG mice. For the LuCAP-77 male NSG mice (Jackson Laboratories, Sacramento, CA) aged 6 to 7 weeks old were transplanted in the right flank subcutaneously with tumor fragments without addition of DHT pellets. For LuCAP-96.1 tumors male C.B-17 SCID.bg mice were inoculated as above. For the LuCAP-37V model castrated male C.B-17 SCID.bg mice were inoculated as above, without addition of DHT pellets. Tumors were monitored until they reached a mean tumor volume of ~150-350 mm 3 and then animals were randomized into one of four treatment groups (PD analyses (n=5-9 per group); efficacy studies (n=10/group for LUCAP-96.1 and LuCAP-77, 5/group for LuCAP35V): [1] Vehicle controls (0.5% methylcellulose/0.2% Tween-80 in water and 1% carboxymethylcellose/0.1% Tween-80/5%DMSO in water (100 µL total), dosed twice daily (BID) via oral gavage (PO)); [ for efficacy studies (100 µL total), dosed twice daily (BID), PO); [3] enzalutamide (10 mg kg −1 (100 µL total) PO, QD), and [4] GNE-049 plus enzalutamide at these same doses and schedules.
For PD studies, animals were dosed for 7 days with tumors being collected 3 to 4 hr post-last dose.
Tumor size and body weight measurements were made twice per week. Tumor volumes were measured in two dimensions (length and width) using Ultra Cal-IV calipers (model 54  10  111; 
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AR-Driven Prostate Cancer Cell Lines are Sensitive to CBP/P300 Bromodomain Inhibition
To investigate the role of CBP/P300 in prostate cancer biology, we selected a panel of cell line models in which to evaluate their contribution to cell proliferation ( Fig. 1A) . We identified 6 cell lines with varying AR expression -LNCaP and MDA-PCa2b (AR WT), VCaP (AR overexpressing), 22RV1 (AR splice variant lacking LBD (ΔLBD) (29)), PC3 and DU145 (AR absent). We confirmed that AR-expressing cell lines were dependent on AR for proliferation by siRNA knockdown, using an N-terminally targeted siRNA that down-regulated both full-length and ΔLBD AR ( Fig. 1B and Supplementary Fig. S1A ). We also confirmed that cell lines were dependent on CBP/P300 for proliferation by siRNA knockdown ( Fig. 1C and Supplementary Fig.   S1B ) (30). CBP and P300 co-depletion inhibited proliferation even in cell lines lacking AR, consistent with a core role for these co-activators in transcriptional regulation.
To probe the potential for therapeutic targeting of CBP/P300 in prostate cancer, we generated a small-molecule inhibitor (GNE-049), targeting the chemically tractable bromodomain of CBP/P300 ( Fig. 1D ). We and others have previously shown CBP/P300 bromodomain inhibition to have anti-tumor activity in hematological cancer models (31-33). GNE-049 is a potent inhibitor of both the CBP (IC 50 = 1.1 nM) and P300 (IC 50 = 2.3 nM) bromodomains in a biochemical bromodomain-binding assay ( Supplementary Fig. S1C ). This compound displayed excellent potency (12 nM) in a bioluminescence resonance energy transfer (BRET) cellular assay and inhibited the expression of MYC with an EC 50 of 14 nM in MV-4-11 cells ( Supplementary Fig.   S1D ,E). Importantly, this compound is exquisitely selective for CBP/P300 in general, and remarkably selective (3,850- Table S1 ). The compound afforded a good balance of cell potency, selectivity and favorable PK properties ( Supplementary Fig. S1F ), and was therefore selected for additional studies.
We evaluated the effect of CBP/P300 bromodomain inhibition by GNE-049 on prostate cancer growth in both a two-dimensional (2D) setting with growth of cells on plastic, and a threedimensional setting (3D) setting with growth in soft agar. Proliferation of AR-expressing PC cell lines was significantly impacted by GNE-049 treatment, to an extent greater than enzalutamide, in all models. This effect was observable under both 2D and 3D growth conditions ( Fig. 1E ).
However, viability of AR negative PC3 and DU145 cells was unaffected by GNE-049 treatment under any conditions.
The CBP/P300 Bromodomain is Required for AR Target Gene Expression
To investigate in more detail the selective effect of GNE-049 only on AR-expressing PC cells, we evaluated the impact of CBP/P300 knockdown and GNE-049 on expression of select AR target genes ( Fig. 2A, B ). While GNE-049 did not impact AR levels ( Supplementary Fig. S2A ), it repressed AR target-gene expression in a dose-dependent manner in all three AR-expressing cell lines ( Fig. 2B ), as well as Myc expression in a subset of lines ( Supplementary Fig. S2B ).
Consistent with modulation of the AR signaling axis by GNE-049, enzalutamide was not strongly synergistic with GNE-049 in LNCaP cells, in both gene-expression and cell-viability assays ( Supplementary Fig. S2C, D) . In a cell-viability assay GNE-049 was moderately synergistic with the BET inhibitor JQ1, as reported previously (32) ( Supplementary Fig. S2E ). In all cell lines the extent of AR target gene repression with GNE-049 was greater than that with enzalutamide. In particular, we noted significant repression of AR target-genes in 22RV1 cells, which remain insensitive to enzalutamide due to expression of ARΔLBD. This result suggests that even in the Research.
Author Manuscript Published OnlineFirst on August 17, 2017; DOI: 10.1158/0008-5472.CAN-17-0314 absence of ligand dependence, the co-activator function of CBP/P300 is required for AR-driven gene expression. Consistent with published data, this was recapitulated by CBP and P300 codepletion by siRNA, which also significantly repressed AR target-gene expression ( Fig. 2A ) (30).
To confirm that GNE-049 impacted the full repertoire of AR-regulated genes, we conducted whole transcriptome RNA-sequencing (RNA-seq) of cell lines after 24 h treatment with 1 μM GNE-049 ( Fig 2C) . While we observed no global repression of transcription upon drug treatment ( Supplementary Fig S2F) , Gene-Set Enrichment Analysis (GSEA) indicated that a hallmark set of AR target genes was down-regulated by GNE-049 treatment, implying a significant impact on the transcriptional output of AR ( Fig. 2C ) (34).
The CBP/P300 Bromodomain is Required for the Response to Androgen
The observation that GNE-049 treatment reduced expression of known AR target genes suggests that GNE-049 may directly impact the ability of PC cells to respond to androgen stimulation. To test this, we starved cells of androgen by growth in charcoal-stripped serum (CSS) for 5 days, and then assessed gene expression via RNA-seq after 24 h of stimulation with 0.1 nM R1881 (synthetic androgen). We identified a set of 292 genes induced by androgen in LNCaP cells ( Fig. 3A and Supplementary Table S2 ). GSEA analysis confirmed that this gene set significantly overlapped with previously identified AR target gene signatures (35) ( Fig. 3B ). Cotreatment with 1 μM of GNE-049 in parallel with R1881 stimulation prevented induction of this gene set, in a manner similar to enzalutamide co-treatment ( the presence of 1 μM GNE-049 for 6 days (Fig. 3D ). In particular, we noted significant reduction in proliferation of R1881-stimulated 22RV1 cells in the presence of GNE-049, even though these cells remained unresponsive to enzalutamide in this assay. Taken together, these data suggest that the CBP/P300 bromodomain is required for prostate cancer response to androgen, and imply a direct role for the bromodomain of CBP/P300 in mediating the co-activator function for AR.
Inhibition of the CBP/P300 bromodomain Prevents AR Co-activator Function
We sought to better understand the mechanism by which CBP/P300 functionally regulate the AR transcriptional response by investigating AR and CBP/P300 co-association and localization on chromatin. Consistent with an AR co-activator function, P300 could be co-immunoprecipitated with AR in nuclear extract from LNCaP cells expressing FLAG-tagged AR (Fig. 4A ). We also confirmed the co-localization of these proteins on chromatin by chromatin-immunoprecipitation and sequencing (ChIP-seq) analysis of LNCaP cells after 24h stimulation with R1881 ( Fig. 4B ,C).
Using the set of 292 androgen-induced genes identified by RNA-seq ( Fig. 3a) , we defined a set of direct AR target genes, as those R1881-induced genes with AR peaks located at their promoters or nearby Androgen Responses Element (AREs). This represented 117 of the 292 R1881-induced genes ( Fig. 4B ). Of these genes, 98 (83%) also had overlapping P300 peaks located at their promoters or AREs (Fig. 4B,C) . These data confirm that AR and P300 function together on chromatin.
To test the hypothesis that GNE-049 directly inhibits the AR co-activator function of CBP/P300, we evaluated the impact of drug treatment on acetylation of histone 3 (H3) at lysine 27 (H3K27Ac). H3K27Ac is directly mediated by CBP/P300, and modification of this residue promotes an open chromatin structure, allowing for active gene transcription (36). Consistent with a block in co-activator function, GNE-049 treatment markedly reduced H3K27Ac at AR/P300 overlapping peaks ( Fig. 4C, D) . In addition to changes at specific AR target genes, a reduction in H3K27Ac levels could also be observed globally at enhancers upon GNE-049 treatment ( Supplementary Fig. S3A,B) , indicating a potential impact on other co-activator functions of CBP/P300 in addition to AR. Surprisingly, GNE-049 did not disrupt the interaction between AR and P300 ( Fig. 4A ), nor did it impact AR or P300 recruitment to chromatin by androgen stimulation (Fig. 4C, D) . These data suggest a model wherein GNE-049 inhibits the AR coactivator function of P300, preventing histone acetylation and activation of gene transcription, but not disruption of AR/co-activator complex formation. This implies that the bromodomain, while dispensable for chromatin binding, plays a critical role in the AR co-activator function of CBP/P300.
Endocrine Therapy Resistance Models Remain Sensitive to CBP/P300 Bromodomain
Inhibition
The observation that GNE-049 can significantly inhibit the proliferation of prostate cancer cells suggests such inhibitors may represent a novel therapeutic strategy in this disease. As CRPC remains a major unmet medical need, we wished to further evaluate the effectiveness of GNE-049 treatment in this context. To better model the progression from Castration-Sensitive (CS) to Castration-Resistant (CR) disease, we sought to generate cell line models that recapitulate some of the common mechanisms of androgen therapy resistance, in the same background as a CS model. To this end, we generated LNCaP cell lines over-expressing either WT AR, or F877L mutant AR (ARmut), a mutation identified in patients and known to confer resistance to Fig. S4A ) (11, 37, 38) . As expected, expression of ARmut in LNCaP cells decreased sensitivity to enzalutamide ( Fig. 5A ). However, ARmut protein still coimmunoprecipitated with P300, suggesting a continued requirement for P300 co-activator activity ( Supplementary Fig. S4B ). Consistent with this, ARmut expressing cells remained highly sensitive to GNE-049, with significant inhibition of cell proliferation and AR target gene expression ( Fig. 5A, B ). These data suggest GNE-049 could have significant therapeutic impact in the context androgen therapy resistant disease.
CBP/P300 Bromodomain Inhibitors Show Anti-tumor Activity In Vivo
While cell line models provide an essential tool to dissect the role of CBP/P300 in prostate cancer, their long-term propagation in vitro can lead to adaptation and alterations that may no longer fully recapitulate the clinical disease. To better model the clinical utility of CBP/P300 inhibitors for the treatment of PC, we examined GNE-049 activity in vivo in Patient Derived Xenograft (PDX) models of prostate cancer. These models have been continually propagated in vivo and may therefore better reflect the human disease state (39). Quantitative PCR (qPCR) analysis of tumors after 7 days of treatment with GNE-049, enzalutamide, or the combination of both drugs indicated significant suppression of AR target genes KLK3 (PSA), TMPRSS2, FKBP5
and MYC, in the AR expressing TM00298 PDX model ( Fig. 6A ). Consistent with these findings, GNE-049 treatment significantly impaired the growth of TM00298 tumors, resulting in 55% tumor growth inhibition (TGI), relative to 21% TGI with enzalutamide after 18 days (Fig. 6B ). The utility of GNE-049 was further validated in three additional AR positive PC PDX models. Activity was observed in LuCaP77, LuCaP96.1 and LuCAP35V, both as single agents (86, 75% and 91% TGI, respectively) and when combined with enzalutamide (106%, 118% and 105% TGI, In this study we describe a CBP/P300 bromodomain inhibitor with properties allowing direct in vivo assessment of the role of these co-activators in PC biology. Using the potent and selective inhibitor GNE-049, we demonstrate the requirement for CBP/P300 bromodomain activity for the response to androgen in PC, and for the growth of PC models both in vitro and in vivo.
Specifically, we show that inhibition of the CBP/P300 bromodomain prevents its co-activator function at AR by preventing the acetylation of H3K27 normally associated with androgeninduced recruitment of AR to chromatin. Since we observe no reduction in P300 or AR recruitment to chromatin in response to drug inhibition, the exact mechanism by which the CBP/P300 bromodomain contributes to histone acetylation remains an exciting open question, and a point for further study. Using GNE-049 to probe the role of this domain in PC biology, we demonstrate significant inhibition of AR target gene as well as Myc expression in several CRPC models, leading to a block in proliferation. These models include those with clinically relevant mechanisms of resistance to current therapies.
Based on our findings we propose a model where in CBP/P300 bromodomain inhibition is sufficient to prevent AR activity at chromatin, thereby blocking expression of key proliferative 
Figure 4. Inhibition of the CBP/P300 bromodomain prevents its AR co-activator function A)
LNCaP cells stably-expressing FLAG tagged AR were treated with 1 μM GNE-049 for 24 h. FLAG-tagged AR was then was immunoprecipitated (IP'd) from nuclear extracts with anti-FLAG, or control IgG. IPs were probed for the presence for P300 using anti-P300 antibodies. 4% total extract is shown as an input control. B) Chromatin IP sequencing with anti AR, P300 and histone H3K27Ac antibodies was performed on LNCaP cells after 24 h stimulation with 0.1 nM R1881.
Diagram indicated the overlap between AR, P300 and H3K27Ac peaks at genes induced by R1881 treatment (as determined in Figure 3A Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
